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Abstract
Background: Recessive mutations in WRN gene eliminate WRN protein function (helicase) and
cause Werner syndrome. One of the most important clinical features of Werner syndrome
patients are the premature onset and accelerated atherosclerosis process. Studies carried out on
polymorphic WRN locus have shown that the alleles 1367R and 1074L confer protection for
cardiovascular disease. Given that the levels of plasminogen activator inhibitor type 1 (PAI-1) were
found to be significantly increased in Werner syndrome patients, is quiet possible that PAI-1
expression could be under regulation of WRN helicase. Therefore the purpose of this work was
to evaluate the role of WRN polymorphism in modulating the expression of PAI-1.
Methods: In order to accomplish our aim, an array of primary cultured fibroblasts from normal
adult donors was genotyped for polymorphisms of both the WRN and PAI-1 loci. In addition, steady
state levels of WRN and PAI-1 were measured by semi-quantitative RT-PCR assays in such cultures.
To search for the potential relationship between the lack of WRN protein and PAI-1 expression,
heterozygous cultures of fibroblasts (1367RC/1074LF; WRN  genotype) were treated with a
molecule of interference RNA against WRN messenger RNA (mRNA).
Results: We found that, carriers of 1367R and 1074L alleles of WRN shown to have low amounts
of PAI-1 in plasma (7.56 ± 5.02), as compared with carriers of 1367C and 1074F alleles (16.09 ±
6.03). Moreover, fibroblasts from carriers with these alleles had low expression levels of PAI-1
mRNA. The treatment of heterozygous primary fibroblast cultures (1367RC/1074LF; WRN
genotype) with iRNA against WRN mRNA caused PAI-1 overexpression. Treatment with normal
PAI-1 inducers (TGFβ, TNFα, or insulin) in these cultures and from those with genotypes 1367CC/
1074FF and 1367RR/1074FL resulted in a genotype-dependent PAI-1 expression level.
Conclusion: Our results suggest that polymorphisms in the WRN gene might have a significant
role regulating PAI-1 levels in healthy individuals and "normal states" as well as acute or chronic
stress, obesity, aging, acute inflammation, among others, where characteristic high levels of insulin,
TNF α and TGFβ, could favor PAI-1 high levels in carriers with polymorphic variants (C and F
alleles), beyond the levels reached by carriers with other alleles (R and L alleles).
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Background
Werner syndrome (WS) is caused by the inheritance of
two copies of null mutations in the WRN locus located at
chromosome 8 [1]. WRN product is a helicase involved in
DNA replication and proofreading processes; its muta-
tions eliminate WRN protein function [2], mostly affect-
ing DNA repair [3]. WS is characterized by premature
onset and accelerated progression of age-related diseases
[4]. From these, vascular pathologies that include athero-
sclerosis, arteriosclerosis, medial calcinosis, and calcifica-
tion of heart valves are the major WS pathological
components. Indeed, myocardial infarction (and cancer)
is the most frequent cause of death in WS patients, which
occurs at a median age of 48 years old [4,5]. One of the
first evidences that links WRN to the atherosclerosis proc-
ess during normal aging involves the well known WRN
polymorphisms: C1367R (refSNP ID: rs1346044) and
L1074F (refSNP ID: rs2725362). From these studies it was
suggested that variant 1367C is associated with an
increased risk of myocardial infarction, whereas variant
1074F is linked to coronary stenosis [6,7]. Moreover, it
has been suggested that 1367R allele of the WRN gene
protects against the development of type 2 diabetes melli-
tus [8]. Therefore, we hypothesize that WRN protein
could be relevant for the regulation of the atherosclerosis
process, even in humans without WS. To verify this
hypothesis at the molecular level, we studied the expres-
sion of plasminogen activator inhibitor type I (PAI-1) in
sub-epithelial fibroblasts from humans with differential
WRN polymorphisms C1367R and L1074F. We focused
on PAI-1 because: a) PAI-1 plays a key role in fibrinolysis,
thereby modulating the rate of atherogenesis [9] and, b)
PAI-1 overexpression has been observed both in plasma
and fibroblasts from WS patients [10]. To accomplish this
objective, an array of primary cultured fibroblasts from
healthy Mexican adults was genotyped for polymorphism
at the WRN locus. Moreover, a semi-quantitative RT-PCR
analysis was used to measure the basal level of PAI-1
mRNA and the changes elicited by physiological PAI-1-
inducers (TNFα, TGFβ, or insulin) when the expression of
WRN  from heterozygous 1367CR/1074LF- fibroblasts
was blocked by a molecule of interference RNA (iRNA).
We also studied the effect of inducers on fibroblasts with
different genotypes. We found that WRN polymorphisms
have a significant contribution to determine levels of PAI-
1 expression.
Methods
Subjects
Protocol design was approved by the Ethical Committee
from University of Colima (No. 2006/54); this protocol is
in compliance with the Helsinki Declaration.
One hundred and fifty healthy non-smoking Mexican
male subjects were recruited by advertisement. Volunteers
had no clinical history of hypertension, diabetes or
inflammatory disorders. Haematological and biochemi-
cal tests, including white blood cell count (WBC) and C-
reactive protein (CRP) were determined to reject subjects
with sub clinical inflammation; written informed consent
was obtained from each participant after the procedures
had been fully explained. Thus, samples from subjects
having a BMI lower than 18.5 Kg/m2 or higher than 24.9
Kg/m2 were excluded from this study. Blood samples of
volunteers were taken in the morning to avoid normal cir-
cadian variation in proteins concentrations [11].
PAI-1 concentration was determined by using HPAIKT kit
(Stratech Scientific, Suffolk, England) and following the
manufacturer instructions.
Samples
Explants of dermis (2 mm3) with attached epidermis were
aseptically removed from donors. Subsequently, tissue
was enzymatically dissociated by 5-min incubation with
0.05% trypsin, prepared in phosphate buffer saline (PBS).
Fibroblasts were harvested, then plated and maintained in
DMEM (Life Technologies, Grand Island, NY) plus 10%
fetal calf serum (FCS; Life Technologies, Grand Island,
NY), at 37°C in 5% CO2 atmosphere. In order to obtain
fibroblasts with their cellular cycles synchronized, cul-
tures were grown to confluence and then serum-starved
for 72 h (culture medium containing 0.5% serum). There-
after, cells were re-fed (DMEM + 10% FCS) and twenty
four hours later total RNA and DNA were isolated from
cells.
PAI-1 and WRN genotyping
C1367R and L1074F WRN  polymorphisms and PAI-1
promotor polymorphism -675 4G/5G were determined
by automatic sequencing. Polymorphic fragments of
WRN and PAI-1 were amplified from genomic DNA by
polymerase chain reaction (PCR) in a cycling instrument
iCycler (Bio-Rad, Hercules, CA), with the following prim-
ers: CR1367F: GCCTAATCAGAATGTTAGTT and
CR1367R: CCTCAGTATTGATGCCTACTTC; LF1074F:
CTTGTGAAGAGGCCTATAAACTGG and LF1074R:
GCCTCATCCTTCAAGCTAATGCAG; PAIF: TACCATGG-
TAACCCCTGGTC and PAIR: GGATCTGTTAGTGCAC-
CGAC. Sequencing reactions were performed with a Big
Dye Terminator V3.1 Sequencing kit (Applied Biosystems,
Foster City, CA) following the manufacturer instructions,
purified by DyeEx Spin kit (QIAGEN, Valencia, CA) and
automatically sequenced by ABI PRISM 310 Genetic Ana-
lyzer (Applied Biosystems, Foster City, CA).
Semiquantitative RT-PCR determination of PAI-1 and 
WRN expression
Confluent layers of skin fibroblasts were used for RNA iso-
lation. Total RNA was isolated by Trizol Reagent (GibcoBMC Cardiovascular Disorders 2008, 8:5 http://www.biomedcentral.com/1471-2261/8/5
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BRL, New York, NY). RNA was used to perform a semi-
quantitative RT-PCR analysis for PAI-1 and WRN expres-
sion For each sample 1.0 µg RNA was reverse transcribed
and amplified by Superscript One-Step RT-PCR kit (Invit-
rogen, Carlsbad, CA) following the manufacturer's
instructions using the following set of intron spanning
primers, annealed into the coding sequence in order to
determine splicing variants [12]: ActinF: CTCGTCGTC-
GACAACCGGCT, ActinR: GCCAATGGTGATGACCTGGC,
PAIF: CAAGGATGAGATCAGCACCACAG, PAIR: GGGT-
TCCATCACTTGGCCCATG WRNF: TGACTTCAATCTCT-
GAGGAAG and WRNR: CAGCTCTACCAATCTCCTGA.
PCR products were separated in an agarose gel (2%) elec-
trophoresis and stained with ethidium bromide. The
intensity of the fluorescence was automatically measured
and integrated by gel data acquisition "Gel Doc" (Bio-
Rad, Hercules, CA) software. All RT-PCR experiments were
done in triplicate and 26 amplification cycles were used.
iRNA preparation
The iRNA sequences were as follows: sense UAGUG-
GCACGGUAGAACCAdTT, antisense UUGUUCUAC-
CGUGCCACUdTT. A scrambled sequence was designed
as a mismatch control: sense GUCACACGAUAGCGAG-
GUAdTT and antisense UACCUCGCUAUCGUGU-
GACdTT. These RNA oligonucleotides were synthesized
individually, deprotected and purified by RNase-free
HPLC (Invitrogen, Carlsbad, CA). iRNA and mismatch
RNA (scrambled) duplexes were formed following the
manufacturer instructions.
Transfection with iRNA against WRN messenger
Five fibroblast cultures presenting heterozygosis for
C1367R WRN  and for F1074L WRN  (1367CR/1074FL
genotype) were synchronized and re-fed (DMEM/
10%SFC), to be immediately used for iRNA treatment.
Cells were transfected with 2 µg siRNA/i-Fect complexes
(Invitrogen, Carlsbad, CA) in a 1:4 ratio (w/v) per plate.
Twenty four hours after transfection, cells were treated
with TNFα (150U/mL; Genzyme. Cambridge, MA), TGFβ
(18U/mL; Genzyme. Cambridge, MA) or insulin (1 mg/
mL; Sigma. St. Louis, MO). Twenty four hours later, cells
were harvested and total RNA was isolated. PAI-1  and
WRN expression was evaluated by RT-PCR. The same pro-
cedure was followed for scrambled RNA and control.
Fibroblast cultures with genotypes 1367CC/1074FF and
1367RR/1074FL were treated equally, except for iRNA
treatment. Five cultures for each genotype were used.
Western blot
Cultured fibroblasts treated and untreated with iRNA or
scrambled molecule were lysed with sodium dodecyl sul-
fate (SDS) sample buffer. Proteins were quantified using
the Bradford assay reagent. Equal amounts of protein (50
µg) were separated under denaturing conditions, by SDS-
PAGE on 10–20% polyacrylamide Tris-glycine gels, and
then electroblotted to polyvinylidene difluoride (PVDF)
membrane. Non-specific sites were blocked with 5% non
fat dry milk in 0.2% Tween-20 in Tris-buffered saline
(TBS-T) for 1 hour at room temperature then reacted with
the primaries anti-WRN and anti PAI-1 antibodies for 1
hour, followed by horseradish peroxidase (HRP)-labeled
anti-rabbit IgG (Jackson Laboratories) for 1 hour. The
bands were visualized using an ECL Plus kit (Amersham
Pharmacia Biotech, Amersham, UK). β-actin was detected
as a protein loading control in the same membrane.
Statistical Evaluation
Values are presented as mean ± SD or mean ± SEM. The
difference of PAI-1 levels between genotypes was analyzed
by paired Student's test. One-way ANOVA was used to test
differences in PAI-1 expression trough WRN genotypes
and in WRN  knocking down experiments across treat-
ments (control, scrambled and iRNA). Significant results
from ANOVA were further analyzed by Tukey's post hoc
test. P < 0.05 was considered significant.
Results
Studied population with no evidence of inflammation
PAI-1 is commonly present at low levels in plasma form
healthy humans; however, acute and chronic diseases are
strongly associated with increased PAI-1 expression and
release [13]. Therefore, to avoid that PAI-1 quantification
was not influenced by sub-clinical inflammation, differ-
ent serum markers of inflammation were measured as
well, thereby trying to avoid high or low levels of PAI-1
independently of WRN genotype. Thus, plasmatic con-
centration values of C-reactive protein (CRP), an acute
phase protein, fibrinogen, glucose, creatinine (through
others markers) are shown in Table 1. Such normal values
demonstrate that the studied population (n = 150) did
not have evidence of inflammatory processes.
The amount of PAI-1 in plasma is dependent of the WRN 
genotype
In order to know whether the amount of PAI-1 in plasma
is related of WRN  genotype, PAI-1 concentration was
determined as described in methods. Subsequently, WRN
polymorphisms (rs1346044 and rs2725362) were evalu-
ated from genomic DNA. Table 2 summarizes the amount
of PAI-1 from a Mexican male population endowed with
the following WRN genotypes: 1367CC/1074FF, a geno-
type whose alleles are not related to cardiovascular disease
protection and 1367 CR/1074LL, 1367 RR/1074FL or
1367 RR/1074LL, whose alleles are associated with pro-
tection against cardiovascular disease [6,7]. It was found
that the individuals with 1367CC/1074FF genotype sys-
tematically revealed higher levels of PAI-1 as comparedBMC Cardiovascular Disorders 2008, 8:5 http://www.biomedcentral.com/1471-2261/8/5
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with those with genotypes whose alleles were associated
with protection to cardiovascular disease (P = 0.031).
Dependence of the basal level of PAI-1 expression on the 
WRN genotype
To address whether WRN polymorphisms can modulate
PAI-1 expression, a semiquantitative RT-PCR analysis of
PAI-1 gene expression was done in an array of primary cul-
tured fibroblasts obtained from the same Mexican male
population. Constant amounts of reverse-transcribed
mRNA were amplified together with the constitutive gene
β-actin to normalize PAI-1 expression. Figure 1 shows that
fibroblasts from carriers 1367RR and/or 1074LL expressed
the lowest PAI-1  levels, whereas those carrying the
1367CC and/or 1074FF alleles expressed the highest ones.
These results suggest that WRN may modulate PAI-1
expression or, alternatively, its differential expression may
depend on PAI-1-promoter polymorphisms such as -675
4G/5G [14]. To evaluate the latter possibility, fibroblasts
used for the above experiments were further genotyped for
-675 4G/5G. There were no significant differences in the
steady-state level of PAI-1 among groups with different
PAI-1 genotypes (data no shown).
Effect of the transient knock-down of WRN on PAI-1 
expression
To search for the potential regulatory role of WRN in PAI-
1 expression, five cultures of heterozygous fibroblasts car-
rying the WRN  genotype, 1367CR/1074LF, were trans-
fected with a specific iRNA against WRN  mRNA to
transiently block its expression. The effectiveness of WRN
silencing was evaluated by western blot analysis for each
cell culture, as shown in the autoradiography in Figure 2A.
All of those cell cultures treated with iRNA against WRN
messenger, were not reactive (or scarcely reactive) to the
antibody against WRN. In contrast, cell cultures treated or
not with the scrambled molecule presented a high reactive
signal (data no shown). Thereafter, mRNA levels of WRN
and  PAI-1  were measured in those knocked-down cul-
tures. As expected, fibroblasts showed significant reduced
levels of WRN mRNA at 24 and 48 h post-transfection
(open bars in Figure 2D). During the same period there
was a parallel large enhancement of PAI-1 expression that
reached a maximum of ~400 % 48 h upon transfection
with the iRNA (filled bars in Figure 2D). The effect of the
iRNA on levels of WRN mRNA and PAI-1 mRNA were
reversed after 72 h post-transfection. In contrast, the
Table 1: Biochemical and haematological characteristics of the studied population
Mean ± SD Mean ± SD
Age 45.4 ± 4.4 Fibrinogen (mg/dl) 207.61 ± 33.2
BMI (kg/m2) 23.4 ± 1.2 CRP (mg/l) 0.8 ± 0.16
Glucose (mg/dl) 93.7 ± 7.81 RBC (106/mm3) 4.721 ± 0.98
Urea (mg/dl) 8.86 ± 3.02 Haemoglobin (g/dl) 12.9 ± 2.45
Creatinine (mg/dl) 0.92 ± 0.07 Haematocrit (%) 45.73 ± 2.67
Albumin (mg/dl) 4.23 ± 0.36 WBC (106/mm3) 0.71 ± 0.21
Cholesterol (mg/dl) 150 ± 24 Platelets (106/mm3) 28.67 ± 6.66
Triglycerides (mg/dl) 102 ± 43 PAI-1 (ng/ml) 9.73 ± 6.72
N = 150 individuals. SD = Standard deviation, BMI = Body mass index, CRP = C reactive protein, RBC = red blood cells, WBC = white blood cells, 
PAI-1 = plasminogen activator inhibitor type 1
Table 2: Biochemical and haematological characteristics of individual with differential genotype of WRN
Genotype of WRN 1367CC/1074FF 1367CR/1074LL
1367RR/1074FL
1367RR/1074LL
P value
n2 5 1 2
Fibrinogen (mg/dl) 200.92 ± 7.04 204.81 ± 8.9 0.077
CRP (mg/l) 0.8 ± 0.012 0.8 ± 0.063 0.5
RBC (106/mm3) 4.832 ± 0.206 4.543 ± 0.24 0.139
Creatinine (mg/dl) 0.92 ± 0.056 0.93 ± 0.026 0.458
WBC (106/mm3) 0.69 ± 0.008 0.73 ± 0.05 0.283
PAI-1 (ng/ml) 16.09 ± 1.206 7.56 ± 1.45 0.031
Values are shown as mean ± standard error of the mean. CRP = C reactive protein, RBC = red blood cells, WBC = white blood cells, PAI-1 = 
plasminogen activator inhibitor type 1. The differences between groups were analyzed by paired Student's testBMC Cardiovascular Disorders 2008, 8:5 http://www.biomedcentral.com/1471-2261/8/5
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expression of neither WRN nor PAI-1 was modified by the
scrambled control RNA molecule (Figure 2C). Moreover,
there were no significant differences in WRN and PAI-1
expression between treated and untreated fibroblasts with
the scrambled RNA molecule (data not shown). Taken
together, these results suggest that WRN tightly regulates
PAI-1 expression.
Effect of PAI-1-inducers on PAI-1 overexpression in 
fibroblasts treated with iRNA against WRN
It is well known that signaling molecules including TNFα,
TGFβ and insulin are inducers of PAI-1  expression
[15,16]. To search for the potential cross-talk between the
WRN-dependent regulation of PAI-1 expression and the
signaling pathways used by those physiological PAI-1-
inducers, TNFα (TGFβ, or insulin) was added 24 hours
after heterozygous fibroblasts (1367 CR/1074LF) were
transfected with iRNA against WRN.  PAI-1  and  WRN
expression was measured 24 hours after the addition of
inducers to coincide their maximum effect (24 h) with
that of iRNA (48 h). In cells transfected with the scram-
bled molecule, TNFα (TGFβ, or insulin) produced a large
increase of PAI-1 expression (Figure 3A, filled bars) with-
out any noticeable effect on expression of WRN (Figure
3A, open bars). As expected, in fibroblasts transfected
with the iRNA, there was a reduction in WRN mRNA (Fig-
PAI-1 steady state levels in primary cultures of fibroblasts with several WRN genotypes Figure 1
PAI-1 steady state levels in primary cultures of fibroblasts with several WRN genotypes. WRN C1367R and L1074F 
polymorphisms were determined by automatic sequencing in primary cultured fibroblasts obtained from healthy adult donors; 
steady state levels of PAI-1 were determined by semiquantitative RT-PCR after 26 amplification cycles. One representative aga-
rose gel is shown in inset. Results were normalized to β-actin expression and plotted as mean ± standard deviation of arbitrary 
units. Number of cultures from each genotype is shown above each bar. * Groups used for ANOVA test • Groups with statis-
tic differences against heterozygous carriers (1367CR/1704FL) by Tukey test, P < 0.01. M = molecular weight ladder.
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ure 3B, open bars) and in that condition, TNFα, TGFβ, or
insulin produced a further overexpression of PAI-1 (Figure
3B, filled bars). WRN expression showed no significant
differences among treatments, neither in the scrambled
nor in iRNA transfected cells (Figure 3A and 3B). Moreo-
ver, there were no significant differences in WRN and PAI-
1 expression between treated and untreated fibroblasts
with the scrambled RNA molecule (data not shown).
These results confirm that WRN controls PAI-1 overex-
pression and suggest that when WRN is knocked down,
PAI-1 escapes this control and can be over-induced by
TNFα, TGFβ, or insulin (Figure 3B). Experimental inducer
concentrations (TNFα, TGFβ and insulin) were previously
standardized at 150 U/ml, 18 U/ml and 1 mg/ml, respec-
tively. Higher concentrations did not significantly aug-
ment  PAI-1  expression when they were added to the
PAI-1 expression levels in WRN knocked down fibroblasts Figure 2
PAI-1 expression levels in WRN knocked down fibroblasts. Five synchronized fibroblast cultures presenting heterozygo-
sis for WRN (1367CR/1074LF) were transfected with a molecule of iRNA against WRN messenger (iRNA; panel D), or with a 
scrambled control RNA (Scrambled; panel C). PAI-1 and WRN expression was evaluated by semiquantitative RT-PCR at several 
times post-transfection. Normalized values of mRNA were grouped as mean ± standard error of arbitrary units. ANOVA was 
used to test differences across treatments (control, scrambled and iRNA). * Significant differences compared with scrambled 
by Tukey test; P < 0.01. Cells cultures were subjected to immunoblotting with anti-WRN antibody to monitor WRN knocking 
down (panel A). Semiquantitative RT-PCR was done at 26th cycle of amplification from total RNA isolated from cell cultures, 
products were separated by electrophoresis in 2% agarose gel and stained with ethidium bromide. The intensity of the fluores-
cence was measured and integrated by "Gel Doc" software. All RT-PCR experiments were done by triplicated (panel B) M = 
molecular weight ladder.
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culture medium in normal fibroblast cultures (data not
shown).
Relation between WRN polymorphisms and PAI- 1 
expression induced by TNFα, TGFβ or insulin
Given that WRN polymorphisms may modulate constitu-
tive PAI-1 expression (Figure 1), we examined whether
WRN polymorphisms could affect PAI-1 overexpression
induced by TNFα, TGFβ, or insulin. Therefore, we used
fibroblasts from individuals with the following geno-
types: 1367CC/1074FF, 1367CR/1074FL and 1367RR/
1074FL (we used the last genotype instead of 1367RR/
1074LL, because we had just one culture from an individ-
ual with that genotype). Cultures were synchronized and
re-fed and they were immediately treated with PAI-1
inducers and 24 hours later, cells were used to determine
WRN and PAI-1 expression levels. TNFα, TGFβ, or insulin
elicited significant lower expression of PAI-1 in fibroblasts
with the 1367RR/1074FL genotype compared with that
found in cells with the 1367CC/1074FF genotype (Figure
4). Insulin-dependent overexpression PAI-1 gave also sig-
nificant differences in fibroblasts with the1367CR/
1074FL genotype. We did not find significant differences
when comparing other groups.
Discussion
We have demonstrated a clear role of WRN in regulating
PAI-1  expression because primary cultured fibroblasts
expressed high PAI-1  levels when WRN  mRNA was
blocked by a selective iRNA molecule. This molecular
finding is in agreement with previous observations show-
ing that WS patients, lacking WRN protein action, exhibit
high PAI-1 levels in plasma and their fibroblasts overex-
press PAI-1 [10]. It is accepted that WS patients have pre-
mature and accelerated progression of age-related
disorders that resemble those during normal aging [4,17].
Thus, the WRN-dependent PAI-1 expression reported here
is also in agreement with the fact that both fibroblasts
from elderly people or fibroblasts in replicative senes-
cence overexpress PAI-1 [17-19], in parallel with a reduc-
tion of WRN mRNA [20].
PAI-1 expression levels in response to TNFα, TGFβ, or insulin in WRN knocked down fibroblasts Figure 3
PAI-1 expression levels in response to TNFα, TGFβ, or insulin in WRN knocked down fibroblasts. Five synchro-
nized heterozygous fibroblasts cultures (1367CR/1074LF) were transfected with a molecule of iRNA against WRN messenger 
(B), or with a scrambled RNA as control (A). PAI-1 inducers (TNFα, TGFβ, or insulin) were added 24 hours post-transfection 
and PAI-1 and WRN expression was evaluated by semiquantitative RT-PCR 24 hours after agonist challenge. Normalized values 
of mRNA were grouped as mean ± standard error of arbitrary units. ANOVA was used to test differences across treatments 
(control, scrambled and iRNA). * Significant differences compared with scrambled by Tukey test; P < 0.05 and ** P < 0.01.
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We do not know whether WRN affects PAI-1 expression by
inhibiting its RNA production or by blocking some sign-
aling pathway. We favor the former mechanism because
the transcription efficacy in cells from WS individuals is
reduced to 40–60% as compared with the rate of tran-
scription in cells from normal subjects [21], suggesting
that WRN is implicated in regulating transcription proc-
ess. Further investigation is needed to clarify the precise
relationship between WRN helicase and PAI-1 mRNA.
The polymorphisms studied here are located in the C-ter-
minal region of WRN which contains exonuclease [22],
helicase [23,24] and transactivation activities [6,21],
besides the nuclear localization signal. This region serves
as a binding site for interacting proteins and DNA [25].
The C1367R polymorphism is close to the sequence cod-
ing the nuclear localization signal and adds a basic amino
acid in this region (coded by the R allele), which it has
been suggested that enhances the strength of the nuclear
localization [6]. In other hand, the L1074F polymor-
phism is close to the DNA-binding domain and intro-
duces an aliphatic amino acid (coded by the L allele)
which might influence the transcription efficiency or the
interaction with DNA or other factors [6]. In this context,
our results show that WRN genetic background seems to
influence the level of PAI-1 expression because fibroblasts
from carriers with 1367RR/1074LL WRN  genotype
expressed the lowest PAI-1 mRNA levels, whereas fibrob-
lasts from those carriers with 1367CC/1074FF genotype
expressed the highest ones. In agreement with PAI-1
mRNA data, it was found that the levels of PAI-1 in
plasma had a variability that was according to WRN poly-
morphisms. This variation was independent of inflamma-
tion as long as participants showed normal values of
fibrinogen, WBC and CRP among other inflammation
markers. Taken together, these findings show that poly-
morphisms in WRN gene differentially contribute to the
levels of PAI-1 expression, a regulation that was experi-
mentally revealed upon the disruption of the WRN
expression. Therefore, in healthy individuals WRN may
have clinical significance because polymorphic variants
(C and F alleles) may be prone to increased risk of athero-
sclerosis due to their higher PAI-1 levels.
In this study we also found that TNFα, TGFβ, or insulin
produced a further PAI-1  expression even so WRN
knocked down enhanced it already. This additive effect
was quite expected due to PAI-1 expression was negatively
PAI-1 induced levels in fibroblasts with different WRN genotypes Figure 4
PAI-1 induced levels in fibroblasts with different WRN genotypes. Synchronized fibroblasts with different WRN geno-
types were treated with TNFα, TGFβ, or insulin. Twenty four hours later, PAI-1 and WRN expression was evaluated by semi-
quantitative RT-PCR. Expression results from five cultures were grouped as mean ± standard error of arbitrary units, 
normalized to β-actin expression. ANOVA test was used to determine differences across genotypes * P < 0.01 against 
1367CC/1074FF genotype by Tukey post hoc test.
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and positively regulated by WRN and the PAI-1-inducers,
respectively. The agonist-dependent enhancement of PAI-
1  overexpression was also affected by WRN  polymor-
phisms. That is, polymorphic variants (C and F alleles)
promoting higher PAI-1 levels in plasma and PAI-1 mRNA
also supported a large overexpression of PAI-1 by insulin,
TNFα and TGFβ. WRN polymorphisms may also have rel-
evant clinical significance for "normal states" such as
stress, obesity, aging or acute inflammation, because they
are characterized by high levels of insulin, TNFα, TGFβ
[26-29]. Therefore, carriers with some polymorphic vari-
ants (C and F alleles) will favour PAI-1 higher levels than
those reached by carriers with other alleles (R and L alle-
les). Thus, C and F polymorphic variants may imply and
enhanced risk of suffering various diseases, such as
atherosclerosis [30,31], cancer [32,33], diabetes [34,35],
wound healing failure [36,37], among others.
The WRN-dependent regulation of PAI-1  expression
described in fibroblasts opens an avenue to address
whether a similar effect occurs in other cellular types that
have a greater impact in the systemic amount of PAI-1,
such as vascular smooth muscle, macrophages and
endothelial cells. This potential widespread up-regulation
of PAI-1 expression could be quite relevant for atheroscle-
rosis because it begins as a response to endothelial injury,
and one of the earlier events consist of fibroblasts prolif-
eration and differentiation at the level of the intimal con-
nective tissue. In this layer of the vascular wall, PAI-1 acts
as an inhibitor of the extracellular matrix degradation and
it has been shown that PAI-1 is a critical mediador of inti-
mal growth [38].
Therefore, the up-regulation of PAI-1  from fibroblasts
may play an important role in the molecular pathogenesis
of fibrosis during the atherosclerosis process. Further
work is required analyzing intracellular signalling and
promoter regions implicated in the PAI-1 up-regulation
WRN-dependent.
Conclusion
We conclude that in fibroblasts the WRN protein down-
regulates PAI-1 expression and after knocking down WRN
gene, PAI-1 expression is enhanced. Our results suggest
that polymorphisms in WRN gene significantly contribute
to regulate the levels of PAI-1 expression. In consequence,
WRN polymorphisms may have a relevant clinical signif-
icance in healthy individuals. Since, polymorphic variants
(C and F alleles) favor higher PAI-1 levels and also overex-
press PAI-1 in response to insulin, TNFα and TGFβ; it may
imply an enhanced risk of suffering various conditions,
such as atherosclerosis, cancer, diabetes, wound healing
failure, among other diseases.
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